The Activation of the Phosphotyrosine Phosphatase
(r-PTP
) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation
Tullio Florio,
Sara Arena,
Stefano Thellung,
Rodolfo Iuliano,
Alessandro Corsaro,
Alessandro Massa,
Alessandra Pattarozzi,
Adriana Bajetto,
Francesco Trapasso,
Alfredo Fusco and
Gennaro Schettini
Pharmacology and Neuroscience (T.F., S.A., S.T., A.C., A.M., A.P.,
A.B., G.S.), National Institute for Cancer Research (IST) and Advanced
Biotechnology Center (CBA) Genova 16132, Italy; Department of
Biomedical Sciences (T.F.), Section of Pharmacology, University G.
DAnnunzio of Chieti, Chieti 66013, Italy; Department of Oncology
Biology and Genetics (S.A., S.T., A.C., A.M., A.P., A.B., G.S.),
Section of Pharmacology, University of Genova 16132, Italy; Department
of Clinical and Experimental Medicine (R.I., F.T., A.F.)
University of Catanzaro, Catanzaro 88100, Italy
Address all correspondence and requests for reprints to: Professor Gennaro Schettini, Neuroscience and Pharmacology, Advanced Biotechnology Center (CBA), Largo R. Benzi, 10, 16132 Genova, Italy. E-mail: schettini{at}cba.unige.it
 |
ABSTRACT
|
---|
The aim of this study was the characterization of the intracellular
effectors of the antiproliferative activity of somatostatin in PC Cl3
thyroid cells. Somatostatin inhibited PC Cl3 cell proliferation through
the activation of a membrane phosphotyrosine phosphatase. Conversely,
PC Cl3 cells stably expressing the v-mos oncogene (PC
mos) were completely insensitive to the somatostatin antiproliferative
effects since somatostatin was unable to stimulate a phosphotyrosine
phosphatase activity. In PC mos cells basal phosphotyrosine phosphatase
activity was also reduced, suggesting that the expression of a specific
phosphotyrosine phosphatase was impaired in these transformed cells. We
suggested that this phosphotyrosine phosphatase could be
r-PTP
whose expression was abolished in the PC mos cells. To
directly prove the involvement of r-PTP
in somatostatins effect,
we stably transfected this phosphatase in PC mos cells. This new cell
line (PC mos/PTP
) recovered somatostatins ability to inhibit cell
proliferation, showing dose-dependence and time course similar to those
observed in PC Cl3 cells. Conversely, the transfection of a
catalytically inactive mutant of r-PTP
did not restore the
antiproliferative effects of somatostatin. PC mos/PTP
cells showed a
high basal phosphotyrosine phosphatase activity which, similarly
to PC Cl3 cells, was further increased after somatostatin treatment.
The specificity of the role of r-PTP
in somatostatin receptor signal
transduction was demonstrated by measuring its specific activity after
somatostatin treatment in an immunocomplex assay. Somatostatin highly
increased r-PTP
activity in PCCl3 and PC mos/PTP
(+300%,
P < 0.01) but not in PCmos cells. Conversely, no
differences in somatostatin-stimulated SHP-2 activity, (
+50%,
P < 0.05), were observed among all the cell lines.
The activation of r-PTP
by somatostatin caused, acting downstream of
MAPK kinase, an inhibition of insulin-induced ERK1/2 activation
with the subsequent blockade of the phosphorylation, ubiquitination,
and proteasome degradation of the cyclin-dependent kinase inhibitor
p27kip1. Ultimately, high levels of p27kip1
lead to cell proliferation arrest. In conclusion, somatostatin
inhibition of PC Cl3 cell proliferation requires the activation of
r-PTP
which, through the inhibition of MAPK activity, causes the
stabilization of the cell cycle inhibitor p27kip1.
 |
INTRODUCTION
|
---|
SOMATOSTATIN (SST) IS a highly expressed
peptide hormone involved in a wide range of biological activities,
including inhibition of pituitary and gastrointestinal hormone
secretion and modulation of neurotransmitter release in the brain
(1, 2).
The effects of SST are mediated by a family of five different G
protein-coupled receptors (named SSTR1 through 5), which are variably
expressed in both normal tissues and tumors (3), often
showing the presence of multiple subtypes in the same cell.
A role for this peptide as endogenous regulator of cell proliferation
in a variety of epithelial (4, 5, 6, 7) and endocrine tissues
has also been proposed (8). In recent years, the molecular
mechanisms involved in this activity have begun to be identified, and
both direct and indirect antiproliferative effects of SST have been
observed. SST indirectly controls cell growth in vivo
through its inhibitory effects on the release of growth-promoting
hormones (9) or through a recently identified
antiangiogenic mechanism involving regulation of proliferation and
migration of endothelial cells as well as monocytes (10).
Moreover, a direct antiproliferative activity in both normal and
tumoral cells has also been reported (2, 9). This effect
is mainly cytostatic (5) although it was reported that the
activation of SSTR3 is able to induce apoptosis (11).
The modulation of phosphotyrosine phosphatase (PTP) activity has been
proposed as being one of the main intracellular pathways responsible
for the inhibition of cell growth by SST (5, 12, 13, 14, 15). A
SST-dependent increase of PTP activity has been shown to induce
dephosphorylation of the epidermal growth factor receptor, inhibiting
the proliferative activity of epidermal growth factor (13, 16). Thus, hormonally-regulated PTPs were proposed to play a key
role in the control of cell proliferation. SST, as well as other
hypothalamic hormones (17, 18, 19, 20), was suggested to be an
important endogenous modulator of the activity of this class of
enzymes. The PTP activity stimulated by SST is associated with the
plasma membrane and shares biochemical features with the phosphatases
SHP1 and SHP2. SHP1 and SHP2 belong to a family of cytosolic PTPs that
contains motifs called src homology 2 (SH2) domains, involved in
protein-protein interaction via their association with specific
phosphotyrosine residues (21). It has been reported that
SHP proteins are rapidly recruited to the plasma membrane upon SST
treatment of breast cancer cells (22). Moreover, SHP PTPs
can be immunoprecipitated in a complex containing SST (23)
or SST receptors (24). Finally, overexpression of an
interfering mutant of SHP2 abolished SST-stimulated membrane-associated
PTP activity (25). More recently, it has been reported
that the antiproliferative activity mediated by SSTR1, transfected in
CHO-K1 cells, was mediated by a SHP2-dependent regulation of MAPK
activity, and that c-src could be the substrate for the PTP
activity regulated by SST (26). Although all this evidence
supports a role of SHPs in SST cell proliferation control, other PTPs
also seem to be involved in the effects of SST. While SHP1 or SHP2
activation by SST occurs after a very short latency time (15 min),
which is followed by a rapid return to basal levels (24, 26), a long lasting PTP activity was also observed in some cell
types after SST treatment, with statistically significant increased PTP
activity even after 2 h of stimulation (5, 15, 27).
This activity was detected in membrane preparations of the responsive
cells, and it was thought to be dependent on the activation of a
still-unidentified receptor-like PTP.
We have recently reported that the SST-dependent cytostatic effects in
the normal thyroid cell line PC Cl3 were mediated by the activation of
a long-lasting membrane PTP activity (5). In an attempt to
identify the molecular correlate for this activity, we evaluated the
effects of SST on both PTP activity and cell proliferation in subclones
of these cells, transfected with different oncogenes, as a model of
malignant transformation (28). By expressing the E1A
and/or middle T oncogenes in these cells, we obtained different cell
lines representing different degrees of malignant transformation. In
particular, wild-type (w.t.) PC Cl3 cells retain most
of the typical markers of thyroid differentiation in vitro,
including dependence on TSH for proliferation and function,
thyroglobulin synthesis and secretion, and the ability to trap iodide
from the medium. In contrast, the cell lines obtained with stable
expression of the E1A and/or middle T oncogenes gradually lost these
differentiative markers, became independent of TSH for proliferation,
and acquired the capability to generate tumors when injected in nude
mice (28, 29, 30, 31). In all the oncogene-transformed cell lines,
SST was unable to inhibit cell proliferation and to stimulate PTP
activity (5, 32). The expression of a newly cloned rat PTP
(32), named r-PTP
on the basis of its homology with the
human DEP-1/HPTP
gene (33), correlated with the lack of
SST efficacy. We therefore proposed that this PTP may be responsible
for the antiproliferative activity of SST. R-PTP
is expressed
ubiquitously, but is mainly found in the brain, liver, and spleen. The
predicted protein contains a unique intracellular catalytic domain, a
short transmembrane domain, and an extracellular region containing
eight fibronectin type III-like repeats (33). The
expression of the r-PTP
gene is induced by TSH in normal thyroid
cells and correlates with their differentiation state; r-PTP
is
down-regulated by transformation induced by several oncogenes as well
as in malignant human thyroid tumors (33, 34).
The aim of this paper was to establish a role for r-PTP
in the
antiproliferative activity of SST. We therefore compared the effects
induced by SST in the w.t. PC Cl3 cells, which express
native r-PTP
, with those obtained in three new subclones of these
cells: 1) PC mos cells (PC Cl3 cells infected with MPSV carrying the
v-mos oncogene) in which the loss of most of thyroid
differentiation markers and the acquisition of autonomous growth and
high tumorigenicity in nude mice correlates with the lack of the
expression of r-PTP
(28); 2) PC mos/PTP
(PC mos
cells in which r-PTP
has been stably retransfected)
(34); and 3) PC mos/PTP
[C/S] (PC mos cells in which a
catalytically inactive mutant r-PTP
has been stably
transfected) (34).
 |
RESULTS
|
---|
Figure 1A
shows Northern blot
analysis of the expression of the mRNA for r-PTP
, in the PC Cl3, PC
mos, and PC mos/PTP
. R-PTP
was expressed in the
w.t. cells, and its expression was lost after cell
transformation by stable expression of the v-mos oncogene.
In the PCmos/PTP
the cDNA for the phosphatase is transfected in the
PC mos cells and the expression of r-PTP
was restored. Equal RNA
loading was demonstrated by evaluation of the GAPDH mRNA content (Fig. 1A
). Similar results were observed in Western blotting experiments
using an
DEP-1 antibody (the human form of r-PTP
) (Fig. 1B
).
Interestingly, the expression of other PTPs involved in the SST signal
transduction, such as SHP2 (26), was not affected in the
PC mos cells (Fig. 1B
).
The proliferative characteristics of PC Cl3, PC mos, and PC mos/PTP
cell lines were studied by means of both DNA synthesis and cell number
analysis, using the [3H]thymidine incorporation
and 3-(4, 5-dimethylthiazol-2-yl)-2,5, diphenyl tetrazolium bromide
(MTT) assays, respectively.
Table 1
shows the time course (up
to 3 d) of the proliferative effects of TSH, insulin, and a
combination of the two factors, analyzed using the MTT test, as cell
number index. In this preliminary experiment, cells were serum- and
growth factor-starved for 24 h and then treated as indicated. In
the absence of growth factors, the w.t. PC Cl3 cells showed
very little proliferative capability and after 4 d (one of
starvation and three of the experiment) clear signs of cell death were
apparent. As previously reported (5), the treatment with
TSH alone had little effect on the mitogenic activity. Conversely,
insulin was a very powerful mitogen, and the combination treatment with
TSH and insulin resulted in a synergistic stimulation of cell growth.
After 3 d of treatment a diminution in cell proliferation,
measured by the MTT test, was observed in the insulin and
insulin+TSH-stimulated cells. This effect is probably due to contact
inhibition as the cells had reached confluency at that time point. A
different proliferation pattern was observed in the PC mos cell line.
In these cells, similar to the other transformed PC Cl3 subclones
(32), up to 3 d of serum starvation did not arrest
the proliferative activity. Conversely, these transformed cells showed
an autonomous pattern of proliferation, since stimulation with the
mitogen (insulin and insulin+TSH) did not significantly increase the
proliferation rate. In the PC mos/PTP
cells an intermediate pattern
of response was observed. Although less pronounced than in PC mos
cells, a proliferative activity, even after 72 h of starvation,
was observed. However, the reexpression of r-PTP
restored the
responsiveness to the growth factors (insulin and insulin+TSH), which
showed a synergistic activity on the proliferation of these cells
(Table 1
).
View this table:
[in this window]
[in a new window]
|
Table 1. Time Course of the Proliferative Effects of
TSH, Insulin, and TSH + Insulin in the PC Cl3, PC mos, and PC
mos/PTP Cell Lines, Evaluated Using the MTT
Test
|
|
The effects of SST on both insulin- and insulin+TSH-stimulated cell
proliferation were also studied using the
[3H]thymidine incorporation assay. In PC Cl3
cells, in agreement with previous data (5, 32), both
proliferative stimuli were suppressed by SST treatment while no SST
effects were observed in the v-mos transformed cells (Fig. 2a
). The expression of r-PTP
in the PC
mos/PTP
cells completely restored SST inhibition of cell
proliferation (Fig. 2A
).

View larger version (34K):
[in this window]
[in a new window]
|
Figure 2. Somatostatin Effects on Cell Proliferation
A, Effect of somatostatin (SST) (1 µM) on insulin (100
nM)- and insulin (100 nM)+TSH (10
nM)-stimulated cell proliferation evaluated by means of the
[3H]thymidine incorporation assay after 24 h of
treatment. Somatostatin inhibition of proliferation, observed in PC Cl3
stimulated with the two growth factors, is abolished in
v-mos-transformed cells while in the PC mos/PTP cells
the antiproliferative effect of somatostatin is completely recovered.
Data are expressed as percentage of basal [3H]thymidine
incorporation activity. Basal values were (counts per min/50,000
cells): PC Cl3 = 367 ± 23; PC mos = 7,893 ± 289;
PC mos/PTP = 4,245 ± 394.  =
P < 0.01 vs. respective basal
values; ** = P < 0.01 vs.
respective insulin- or insulin+TSH-stimulated values. B, Expression of
SST receptor subtypes in PC Cl3, PC mos, and PC mos/PTP evaluated by
means of RT-PCR. The pattern of expression of the receptors was not
changed by v-mos or r-PTP expression. The number of
the lanes corresponds to the SST receptor subtype; "A" represents
amplification of a ß-actin cDNA fragment, used as internal control.
|
|
The lack of responsiveness to SST in the PC mos cells was not due to
the absence of the expression of the SSTRs since all the cloned SSTRs
(SSTR15) were expressed in the PC mos cells as well as in the PC Cl3
cells (Fig. 2B
). A similar pattern of expression was also observed in
the PC mos cells transfected with the cDNA encoding for r-PTP
(Fig. 2B
).
We then performed time course and dose-response experiments to compare
the characteristics of SST cell proliferation inhibition in both the
w.t. cells (which express the endogenous r-PTP
) and the
transformed cells transfected with r-PTP
cDNA. The data reported in
Figs. 3
and 4
, while confirming the
absence of responses in the PC mos cells,
show that the pharmacological profile of the SSTs antiproliferative
effects in the PC Cl3 and PC mos/PTP
cells was almost identical,
having superimposable time course and dose-response curves. Moreover,
to demonstrate that the recovery of the responsiveness to SST in PC
mos/PTP
was specifically due to r-PTP
and not to the transfection
procedure and clonal selection, we analyzed the effect of SST on
insulin+TSH-stimulated cell growth in PC mos cells transfected with a
catalytically inactive mutant of r-PTP
(PC mos/PTP
[C/S]). This
cell line showed growth characteristics identical to the PC mos cells
(only a 12% increase in proliferative activity after insulin+TSH
stimulation); SST (0.0110 µM) did not
affect the proliferation of these cells (Fig. 4).

View larger version (17K):
[in this window]
[in a new window]
|
Figure 3. Time Course of the Antiproliferative Effects of SST
on PC Cl3, PC mos, and PC mos/PTP Cell Growth Induced by
Insulin+TSH, Evaluated Using the MTT Test
The expression of the mos oncogene caused an abolishment
of the sensitivity to SST, while the transfection of r-PTP favored
the restoration of the inhibitory response to SST. Data are expressed
as percentage of the absorbance values measured at time 0. **,
P < 0.01 vs. respective TSH+insulin
values.
|
|
Almost all the physiological effects mediated by SSTR are dependent on
the activation of a pertussis toxin (PTX)-sensitive GTP-binding protein
(for review see ref. 35). Therefore, we also tested the role of G
proteins in the antiproliferative activity of SST in the different cell
lines. PTX pretreatment (180 ng/ml, 18 h) completely reverted the
inhibitory effects of SST in PC Cl3 and PC mos/PTP
cells (Fig. 5
), indicating that the signal
transduction activated by this peptide was dependent on the activation
of a G protein that appears to belong to the
Gi/G0 family. Again, no
effects were detected in the PC mos cells (Fig. 5
). These data show
that the antiproliferative effects of SST in these thyroid cell lines
were correlated with the expression of r-PTP
. To more directly
demonstrate the involvement of a PTP in SST activity, we treated the
cells with vanadate, a selective inhibitor of all the PTPs. As shown in
Fig. 6
, vanadate (25 µM)
treatment increased basal [3H]thymidine
incorporation in PC Cl3 cells, confirming that a basal PTP activity was
present that could maintain a low rate of cell proliferation.
Pretreatment with the PTP inhibitor completely reverted the inhibitory
activity of SST on both insulin- and insulin+TSH-stimulated conditions.
In the transformed PC mos cells, in which r-PTP
was completely
down-regulated, vanadate did not modify the basal activity, suggesting
the loss of cell proliferation control by a PTP, likely r-PTP
. In
addition, no effects of SST or vanadate were observed in
TSH+insulin-stimulated conditions. In PC mos/PTP
cells, vanadate
pretreatment increased basal [3H]thymidine
uptake, confirming that the lack of effects observed in the PC mos
cells was due to the lack of expression of r-PTP
. Similarly,
vanadate completely reverted the inhibitory activity of SST in
stimulated conditions, showing a pattern of response similar to that
observed in the w.t. PC Cl3 cells (Fig. 6
). Using the
synthetic substrate p-nitrophenylphosphate (pNPP), we
directly measured the SST-inducible total membrane PTP activity in the
different cell lines (Fig. 7
). The
expression of the oncogene v-mos in the PC Cl3, which caused
a down-regulation of r-PTP
gene expression, significantly reduced
the total membrane PTP activity (
-50%), together with the
disappearance of the SST-dependent (1 µM,
1 h of treatment) increase in PTP activity observed in the PC Cl3
cells. In the PC mos/PTP
cells, basal PTP activity increased to
levels similar or even higher than those observed in the PC Cl3 cells.
More importantly, the expression of r-PTP
in the PC mos cells
totally restored the stimulation of a membrane PTP activity by SST
(Fig. 7
). The PC mos/PTP
[C/S] cells, which express the
catalytically inactive mutant of r-PTP
, showed the same pattern of
response as the PC mos cells (low basal level and lack of response to
SST) (Fig. 7
). Moreover, we directly evaluated the specific r-PTP
activity in these cell lines after SST treatment (1
µM). As a control we evaluated the SST
modulation of another PTP, SHP2, endogenously expressed in all the cell
lines used in this study (Fig. 1B
), which was previously described to
be activated by SST (26). Because different kinetics of
activation between these two PTPs were reported (5, 26),
we analyzed SST effects after both 10 min and 1 h of treatment.
The experiments were performed in an immunocomplex assay. After
insulin+TSH and insulin+TSH+SST treatments, cells were lysed and
immunoprecipitated with
SHP2 and
PTP
antibodies, and PTP
activity, measured as hydrolysis of pNPP, was assayed in the
immunocomplexes. An aliquot of the immunoprecipitate was analyzed in
Western blot to normalize the level of r-PTP
and SHP2 proteins in
the pNPP hydrolysis assay. As shown in Fig. 8C
, the level of SHP2 immunoprecipitated
was similar in all the cell lines and for all the treatments. As
expected, no r-PTP
was immunoprecipitated in PC mos cells, although
the level of protein detected in the other cell lines was comparable
for all the treatments (Fig. 8C
). The PTP activity experiments
showed that r-PTP
activity was increased after only 10 min of SST
treatment (+300%) in both PC Cl3 and PC mos/PTP
cell lines. If
compared with the untreated or insulin+TSH-treated cells, the activity
was still significantly higher after 1 h of stimulation
(+150%)(Fig. 8A
). As expected, no r-PTP
specific activity was
detected in the PC mos cell line (Fig. 8A
). Conversely, 10 min of SST
treatment significantly increased SHP2 activity to a similar level in
all the cell lines (
+50%), but after 1 h of SST treatment,
SHP2 activity returned to the basal level (Fig. 8B
).

View larger version (40K):
[in this window]
[in a new window]
|
Figure 5. Involvement of PTX-Sensitive G Protein on the
Activity of SST in PCCL3, PC mos, and PCmos/PTP
Cells were pretreated with the PTX (180 ng/ml) for 18 h and then
treated for 24 h with TSH and insulin in the presence or absence
of SST. Data are expressed as percentage of TSH+insulin-stimulated
conditions. Basal values were (counts per min/50,000 cells): PC
Cl3 = 524 ± 43; PC mos = 8,913 ± 779; PC
mos/PTP = 5,655 ± 416. **, P < 0.01
vs. respective TSH+insulin values.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
Figure 6. Effect of Vanadate (25 µM)
Pretreatment on SST Inhibition of PC Cl3 (upper panel),
PC mos (middle panel) and PC mos/PTP (lower
panel) Cell Proliferation
Data are expressed as percentage of basal [3H]thymidine
incorporation activity. °, P < 0.05; and °°,
P < 0.01 vs. respective basal
values; ##, P < 0.01 vs. respective
insulin value; ++, P < 0.01 vs.
respective insulin+TSH values.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Figure 7. Total PTP Activity in Membrane Preparations Derived
from PC Cl3, PC mos, PC mos/PTP , and PC mos/PTP [C/S] cells in
the Presence or Absence of SST (1 µM, 1 h), Measured
Evaluating The Hydrolysis of the Synthetic Substrate pNPP, in a
Spectrophotometric Assay
**, P < 0.01 vs. respective basal
values; °, P < 0.05 vs. PC Cl3
basal value.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Figure 8. Somatostatin-Specific Activation of r-PTP and
SHP2
A, r-PTP specific activity in PC Cl3, PC mos, and PC mos/PTP
after 10 min or 1 h of treatment with vehicle or insulin (100
nM)+TSH (10 nM) in the presence or absence of
SST (1 µM). After the treatment 250 µg of total cell
lysate were immunoprecipitated with -r-PTP antibody, and the
immunocomplexes, isolated using protein A-coated magnetic beads
(Dynabeads), were tested in the PTP assay. The hydrolysis of pNPP, used
as substrate, was detected in a spectrophotometric assay (O.D. 410 nm).
B, SHP2 specific activity in PC Cl3, PC mos, and PC mos/PTP in basal
conditions or after 10 min or 1 h of stimulation with insulin (100
nM)+TSH (10 nM) in the presence or absence of
SST (1 µM). After the treatment, 250 µg of total cell
lysate were immunoprecipitated with -SHP2 antibody, and the
immunocomplexes, isolated using protein A-coated magnetic beads
(Dynabeads), were tested in the PTP assay. The hydrolysis of pNPP, used
as substrate, was detected in a spectrophotometric assay (O.D. 410 nm).
C, Western blot (using -r-PTP or -SHP2 antibodies) on an
aliquot of the immunoprecipitated proteins, to compare the amount of
specific proteins used in the PTP assay. *, P <
0.05 and ** = P < 0.01 vs.
respective basal values.
|
|
It was previously reported that r-PTP
was able to control cell
proliferation through a stabilization of the cyclin-dependent kinase
(CDK) inhibitor p27kip1 (34). In the
different cell lines, we evaluated whether the SST treatment was able
to increase the amount of nuclear p27kip1 and
whether this effect correlated with the activation of r-PTP
. For
this purpose we analyzed by immunofluorescence confocal microscopy the
nuclear presence of p27kip1 using a specific
polyclonal antibody. In
G0/G1 synchronized
w.t. PC Cl3 (24 h of serum and growth factor deprivation) a
clear nuclear expression of p27kip1 was observed
(Fig. 9a
). The nuclear staining was
greatly reduced after TSH+insulin treatment (Fig. 9b
). SST powerfully
inhibited the degradation of p27kip1 in
stimulated conditions, suggesting that the cytostatic signals, mediated
by the SST-sensitive PTP, have p27kip1 as a
nuclear effector (Fig. 9c
). In PC mos cells
p27kip1 levels were extremely low after 24 h
of starvation and did not change after insulin+TSH or insulin+TSH +SST
treatments (Fig. 9
, d, e, and f). The expression of r-PTP
in the PC
mos cells restored both the basal levels of
p27kip1 and the sensitivity to SST. Indeed, the
mitogenic stimuli (TSH+insulin) significantly reduced the number of
p27kip1 positive cells (>80% of the cells did
not show any immunostaining for p27kip1), while
cotreatment with SST reversed this effect, showing more than 70% of
positive cells (Fig. 9
, g, h, and i). Similar results were obtained in
Western blot experiments using a p27kip1
selective antibody (Fig. 10
). In PC Cl3
and PC mos/PTP
cells, basal p27kip1 expression
was significantly reduced by the mitogenic insulin+TSH stimulation,
while SST treatment prevented this effect. Interestingly, the
pretreatment with the MAPK kinase (MEK) and proteasome
inhibitors, PD98059 and ZIE [Ot-Bu]-A-leucinal (PSI), respectively,
per se ineffective (data not shown), inhibited the reduction
in p27kip1 cell content induced by insulin+TSH
stimulation (Fig. 10
), suggesting that the decrease in the
concentration of this CDK inhibitor requires the activation of ERK1/2
which through the phosphorylation of p27kip1
induces its ubiquitination and proteasome degradation, as recently
reported (36). Moreover, this result indicates that SST
negatively interferes with this pathway. In PC mos cells, the basal or
insulin+TSH levels of p27kip1 were extremely low
and were not affected by SST treatment. Conversely, both PD98059 and
PSI significantly increased the p27kip1 content
in both basal (data not shown) or insulin+TSH-stimulated
conditions, indicating that ERK1/2 and proteasome activation were
downstream to the v-mos effects. The relevance of
p27kip1 expression for the growth
factor-dependent proliferation of all the cell lines was also
demonstrated evaluating the effects of the PD98059 and PSI compounds on
the insulin+TSH-stimulated cell growth. In these experimental
conditions both basal (in the PC mos cells) and insulin+TSH-stimulated
(in PC Cl3 and PC mos/PTP
cells) proliferation was completely
blocked (data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
Figure 9. Detection of Nuclear Presence of
p27kip1 by Immunofluorescence Using a Polyclonal Antibody
in PC Cl3 (a, b, c), PC mos (d, e, f), and PC mos/PTP (g, h, i)
Panel a, Immunoreactivity for p27kip1 in PC Cl3 cells after
a 24-h starvation. p27kip1 nuclear expression is greatly
reduced after treatment with insulin+TSH (panel b), while treatment
with SST restored basal levels of p27kip1 (panel c). In
G0/G1 synchronyzed PC mos cells
p27kip1 was not detectable in the nucleus (/panel d) as it
was not after the treatment with the growth factors (panel e) and after
the addition of somatostatin (panel f). The expression of r-PTP is
responsible for the nuclear induction of p27kip1 in 24-h
starved PC mos/PTP cells (panel g). p27kip1 positive
cells are less than 20% after growth factor stimulation (panel h),
while a significant immunostaining for p27kip1 was observed
when treated with SST (panel i).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Figure 10. Expression of p27kip1, in the
Different Cell Lines, Measured by Western Blot Analysis
1, Untreated (control) cells; 2, insulin (100 nM)+TSH (10
nM) treatment for 4 h; 3, insulin+TSH+SST (1
µM) treatment for 4 h; 4, insulin+TSH+PD98059 (10
µM) treatment for 4 h; 5, insulin+TSH+PSI (10
µM) treatment for 4 h.
|
|
To identify the possible level of action of r-PTP
activity induced
by SST, we evaluated the phosphorylation state (activation) of
different components of the insulin-dependent proliferative pathway:
the insulin receptor-ß (IRß) subunit, MEK and ERK1/2. To
evaluate the effects of SST on the insulin-dependent IRß tyrosine
phosphorylation, serum-starved PC Cl3, PC mos, and PC mos/PTP
cells
were treated for 5 min with 100 nM insulin in the presence
or absence of 1 µM SST and then immunoprecipitated with
-IRß antibody and evaluated with
-phosphotyrosine antibody in
Western blot (Fig. 11
), or vice versa
(data not shown). Insulin treatment induced a significant
phosphorylation of its receptor, and SST significantly inhibited this
effect in all the cell lines. MEK activation was tested in all the cell
lines in basal and insulin+TSH- or insulin+TSH+SST-stimulated
conditions (Fig. 12
). In PC Cl3 cells
insulin+TSH increased MEK phosphorylation while SST completely blocked
this effect. Conversely, in PC mos and PC mos/PTP
MEK,
phosphorylation was already elevated in basal conditions, probably due
to the expression of mos, of which MEK is a direct substrate. However,
in both cell lines, neither insulin+TSH nor insulin+TSH+SST treatments
modified this effect.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 11. Reversal by SST of the Insulin-Dependent Tyrosine
Phosphorylation of the IRß-Subunit in PC Cl3, PC mos, and PC
mos/PTP Cell Lines, Measured in Western Blot after
Immunoprecipitation, as Indicated
C, Untreated (control) cells; I, insulin (100 nM); I+S,
insulin + SST (1 µM).
|
|

View larger version (38K):
[in this window]
[in a new window]
|
Figure 12. Somatostatin Regulation of MEK and ERK1/2
Activities
A, Effect of SST treatment on TSH+insulin-dependent MEK (left
panels) and ERK1/2 (right panels)
phosphorylation in PC Cl3, PC mos, and PC mos/PTP cell lines. B,
Normalization of the results obtained with the phospho-specific
antibodies, evaluating total MEK and ERK1/2 expression in the
different cell lines. C, Untreated (control) cells; TI, TSH (10
nM)+insulin (100 nM) treatment for 10 min.;
TIS, TSH+insulin+SST (1 µM) treatment for 10 min.
|
|
As far as ERK1/2 activation is concerned, in PC Cl3 cells (as well as
in PC mos/PTP
cells), insulin+TSH treatment (100 nM and
10 nM, respectively) significantly increased ERK1/2
phosphorylation, and SST completely reverted this effect. In PC mos
cells basal ERK1/2 phosphorylation was significantly elevated, and
neither insulin+TSH nor insulin+TSH+SST treatments were able to modify
it (Fig. 12
).
Interestingly, other signal transduction systems were not recovered
after r-PTP
expression in the PC mos cells. Indeed, similarly to the
transformed cells, in the PC mos/PTP
the treatment with TSH did not
induce an increase in intracellular calcium concentration
([Ca++]i), as observed in the w.t. PC Cl3 (Fig. 13
).

View larger version (20K):
[in this window]
[in a new window]
|
Figure 13. Microfluorimetric Analysis of the Increase in
[Ca++]i Elicited by TSH, using the Fluorescent Probe Fura
2
In the graph are reported the mean values of at least 10 cells,
individually analyzed. SE was less than 5% for all the
values. The expression of the mos oncogene completely
abolished the TSH-induced calcium increase, and the coexpression of
r-PTP did not modify this effect.
|
|
Moreover, the specificity of the coupling of r-PTP
to the
antiproliferative activity of SST was studied analyzing the capability
of TGFß1 to control the proliferative activity in the different cell
lines we studied. The data in Fig. 14
show that, irrespectively to the expression of r-PTP
, TGFß1
induced a significant inhibition of
[3H]thymidine uptake, in all the cell lines
studied. Moreover, the dose-responses of TGFß1 observed in the
w.t. PC Cl3, PC mos, and PC mos/PTP
cell lines were
almost superimposable, showing that the expression of r-PTP
is not
necessary for the antiproliferative activity of TGFß1 and confirming
that this PTP may represent a specific effector in the signal
transduction of SSTRs, to control cell proliferation.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 14. Effect of Different TGFß1 Concentrations (1, 5,
and 10 nM) on the DNA Synthesis Induced by Insulin+TSH
Stimulation, Evaluated by Means of [3H]Thymidine Uptake
Assay
Data are expressed as percentage of the TSH+insulin stimulation of DNA
synthesis. *, P < 0.05; and **,
P < 0.01 vs. respective TSH+insulin
values.
|
|
 |
DISCUSSION
|
---|
In the present study we have characterized the role of the
receptor-like PTP, r-PTP
, in the antiproliferative activity of SST
in the PC Cl3 clonal thyroid cell line.
PC Cl3 cells are dependent on insulin and TSH for their proliferation,
and the activation of SSTRs mediates the generation of cytostatic
signals (5). In these cells, the antiproliferative
activity of SST is dependent on the activation of a membrane-associated
PTP through a PTX-sensitive GTP-binding protein. In the past, the
involvement of PTPs in the antiproliferative effects of SST and other
endogenous compounds, such as dopamine, angiotensin II, and LHRH, was
well characterized (16, 17, 18, 19). More recently, in an effort
to identify at molecular level the PTP(s) involved in the
antiproliferative activity of SST, many studies identified the
SH2-containing PTPs as effectors of different SSTRs. However these
PTPs, namely SHP1 and SHP2, cannot account for all the PTP activities
induced by SST. Indeed, while the activation of SHP1 and SHP2 occurs
very rapidly (0.53 min) and is rapidly inactivated (
10 min)
(24, 26), in different experimental models a SST-inducible
long lasting PTP activity (still elevated after 1 h of treatment)
was reported (13, 15, 27). Also in PC Cl3 cells we
previously reported (5, 32), and confirmed in this study,
a stimulatory effect on a membrane PTP activity after 1 h of SST
treatment.
The main goal of our work was to identify, at molecular level, a
possible candidate for this PTP activity. For this purpose we used a PC
Cl3 subclone that was stably infected with the plasmid MPSV carrying
the oncogene v-mos (PC mos). These cells acquire a
transformed phenotype and loose the thyroid differentiation markers.
Like other transformed subclones of PC Cl3 cells (stably expressing the
oncogenes E1A and/or middle T) (32), PC mos cells show an
autonomous pattern of proliferation, probably due to the constitutive
activation of the ERK1/2 pathway that occurs by the direct MEK
phosphorylation induced by the active mos oncogene. Moreover, they are
insensitive to the antiproliferative effects of SST. These growth
characteristics correlate with the loss of the expression of the
receptor-like r-PTP
, while other PTPs, such as PTPµ
(32) or SHP2 (present paper) are unaffected. r-PTP
is
expressed in most of the normal rat tissues, and the reduction of its
expression was observed in most oncogene-transformed thyroid cell lines
(33). Interestingly, a down-regulation of the expression
of the human homolog of r-PTP
, DEP-1/HPTP
, was also observed in
human malignant thyroid tumors, suggesting that this PTP may represent
an important regulator of thyroid cell differentiation and
transformation, behaving as an oncosuppressor gene (34).
Indeed, the stable expression of r-PTP
in the transformed PC mos
cells was sufficient to cause a partial recovery of thyroid
differentiation markers and a reduction of the growth potential of the
transformed cells. In particular, the mechanisms controlling the
proliferation, such as contact inhibition, were restored in these cells
through an increase in the steady-state level of the cyclin-dependent
kinase inhibitor p27kip1 (Ref. 34
and present paper). This effect was specific for r-PTP
since the
transfection of another receptor-like PTP, PTP
, did not cause the
reversion of the transformed phenotype (34). In this paper
we evaluated the involvement of r-PTP
in the antiproliferative
signals induced by SST. Indeed, while in the w.t. PC Cl3
cells SST seems to be one of the major inhibitors of the proliferative
pathways, this control is completely lost in the transformed PC mos
cells. The lack of responsiveness to SST in PC mos cells is not due to
an alteration in the mRNA expression of SSTR, which is not changed in
the different cell lines, but seems due to the down-regulation of
r-PTP
. Indeed, in the PC mos/PTP
cells a complete recovery of the
SST control of cell proliferation was observed. Conversely, the
transfection of a catalytically inactive mutant of r-PTP
in the PC
mos cells did not cause any recovery of the antiproliferative effects
of SST. In PC mos/PTP
cells, the expression of r-PTP
restored the
PTP tonic activity that controls basal cell proliferation, as
demonstrated by the capability of vanadate to increase basal
proliferative activity that correlated with a reduction in the basal
proliferation rate, features also observed in the w.t. PC Cl3 cells.
More importantly, the expression of r-PTP
was absolutely necessary
for the SSTergic PTP-mediated control of cell proliferation. Indeed,
the transfection of r-PTP
in the PC mos cells restored the
responsiveness to SST with pharmacological characteristics
superimposable to that observed in the w.t. cells. SST treatment was
able to induce a membrane PTP activity only in the r-PTP
-expressing
cell line. Immunocomplex assays showed that this activity was mainly
ascribable to r-PTP
, the activity of which was increased by 300%.
However, the specific activity of SHP2, another SSTR-regulated PTP
(26), was also increased although to a much lower level
(150% of the basal) irrespective of the modulation of cell
proliferation induced by SST. This observation suggests that, at least
in these cells, SHP2 activity is not sufficient, to inhibit cell
growth. Conversely, the activation of r-PTP
was absolutely
necessary for such an effect.
Interestingly, although PC mos/PTP
cells show a higher proliferation
rate compared with the w.t. PC Cl3 cells, the dose-response
curves, time course, and G protein dependence of the antiproliferative
effects of SST were similar in the two cell lines, indicating that the
exogenous expression of this PTP did not alter the normal regulation of
its activity and final physiological effects. The role of
r-PTP
in the control of cell proliferation seems to be selective for
the signal transduction activated by the SSTR, since no alterations in
the antiproliferative effects of TGFß1 were observed in the
transformed cells, regardless of the expression of r-PTP
. Similarly
the transfection of r-PTP
did not cause, in the PC mos cells, the
recovery of other transduction signals lost in the transformed cells,
such as the mobilization of intracellular Ca++
observed in the PC Cl3 cells, which was probably involved in biological
functions other than cell proliferation (i.e. hormonal
secretion). These data demonstrate that r-PTP
is mainly
responsible for the control of the antiproliferative signals in these
thyroid cell line and that its activation is selectively regulated by
SST receptors.
The inhibition of ERK1/2 phosphorylation, with the subsequent
ubiquitination and proteasome-dependent proteolytic degradation of the
CDK-inhibitor p27kip1, was recently reported to
represent an important mechanism of cell cycle arrest in normal and
tumoral cells (36). Moreover, r-PTP
was shown to
represent a possible regulator of p27kip1
expression (34). Here we report that the activation of
r-PTP
by SST is able to revert the activation of the proteolytic
degradation of p27kip1 induced by the treatment
with TSH and insulin, an effect dependent on the blockade of the
insulin-stimulated ERK1/2 activation. Next, we tried to identify
possible substrates dephosphorylated by r-PTP
, after SST
stimulation. We found that in all the cell lines (including the PC mos
cells that do not express r-PTP
), SST caused dephosphorylation of
the insulin-phosphorylated IRß, thus indicating that in these cells
SST inhibition of IR activation is not mediated by r-PTP
.
Interestingly, the recombinant human homolog of r-PTP
, DEP-1, was
reported to be unable to dephosphorylate in vitro a
tyrosine-phosphorylated IRß (37). Conversely, it was
reported that SSTR2 activation caused, in CHO cells, dephosphorylation
of IRß through the activation of SHP1 (38). Since in our
cell system SST causes, in all the cell lines, the activation of the
related PTP SHP2, we can speculate that also in thyroid cells the
dephosphorylation of the IRß may be mediated by SST through SHP2.
Thus, r-PTP
specific target seems to be downstream from IRß in the
signal transduction cascade. We evaluated MEK and ERK1/2
phosphorylation after SST-induced PTP activation. We found that the
activation of both kinases was inhibited by SST in PC Cl3 cells, and
that MEK phosphorylation was not affected in PC mos and PC mos/PTP
.
Since in these cell lines the oncogene v-mos, which is able to directly
phosphorylate MEK, is constitutively expressed, the lack of effects of
SST in the PC mos/PTP
cells clearly suggests that the activity of
r-PTP
should be downstream from MEK. Indeed, we found that,
similar to w.t. PC Cl3 cells, in PC mos/PTP
, SST treatment
caused a significant reduction of the insulin-dependent ERK1/2
phosphorylation. Although we do not have evidence of a direct
interaction, we propose that r-PTP
activation leads to the
inhibition of ERK activity, either through a direct dephosphorylation
or through the regulation of still unidentified intermediate proteins.
Interestingly, other PTPs, namely PTP-SL and striatum enriched
phosphatase, were previously reported to directly interact and
dephosphorylate ERK1/2 (39). Thus, we propose that, at
least in PC Cl3 cells, SST is able to exert a cytostatic activity
through the control of p27kip1 expression,
mediated by the activation of r-PTP
that, acting directly or
indirectly, downstream of MEK, interferes with the insulin-dependent
ERK1/2 activation. The establishment of a role for the control of
p27kip1 expression in the SST cytostatic effects
is in agreement with previous observations showing, in different cell
lines, a SST-dependent blockade of the growth factor-induced
p27kip1 degradation, although through different
mechanisms. In the FRTL-5 thyroid cell line, the cytostatic effects of
SST were mediated by the inhibition of the down-regulation of
p27kip1 induced by the TSH-dependent PKA and PI3K
activation, via an interference with cAMP generation (40, 41). Conversely, in CHO-k1 cells overexpressing SSTR2, SST was
reported to induce a stabilization of p27kip1
levels in a PTP-dependent manner involving SHP1 (42).
In our experimental model SST is able to block the
insulin-induced degradation of p27kip1 by
preventing the activation of the ERK1/2 pathway, via the activation of
r-PTP
(Fig. 15
).
In conclusion, in this paper we demonstrate that in the PC Cl3
thyroid cell line, SST is able to activate the receptor-like PTP
r-PTP
, which mediates the antiproliferative signals activated by
SSTR, including the stabilization of the CDK inhibitor
p27kip1, acting directly as an inhibitor of
growth factor-mediated ERK1/2 activation. This observation shows, for
the first time, the capability of G protein-coupled receptors to
regulate the activity of receptor-like PTPs to control cell
proliferation. The intracellular pathway leading to the activation of
r-PTP
by SST is still to be determined, and we cannot exclude the
involvement of other cytosolic PTPs such as SHP-1/2, as reported
in other cell systems.
 |
MATERIALS AND METHODS
|
---|
Materials
SST, PD98059, ZIE [Ot-Bu]-A-leucinal (PSI), and TGFß1were
purchased from Calbiochem (Lucerne, Switzerland), and
vanadate was obtained from ICN Biochemicals, Inc.
(Cleveland, OH); all other reagents were from Sigma
(Milano, Italy) unless otherwise specified.
Antibodies
For r-PTP
detection, we used antibodies raised against the
intracellular region of r-PTP
expressed as a recombinant protein
fused to GST, and affinity purified (34), used in Western
blot experiments at the dilution of 1:500. Other antibodies used were:
p27kip1 (clone 57) (Transduction Laboratories, Inc., Lexington, KY), p44/42 and phospho-p44/p42
MAPK, MEK and phospho-MEK (New England Biolabs, Inc.,
Beverly, MA), SHP2 (C18) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) phosphotyrosine P-Tyr-100 (Cell Signaling Technology,
Beverly, MA), all used at the dilution of 1:1,000; IRß (clone 46)
(Transduction Laboratories, Inc.) was used at the dilution
of 1:250.
Cell Culture
PC Cl3 and PC mos/PTP
cell lines were
grown in Hams F12 medium, Coons modification (Sigma)
supplemented with 5% FCS (ICN) and a mixture of growth factors
(TSH, 10 nM; hydrocortisone, 10 nM; insulin,
100 nM; transferrin, 5 µg/ml; glycyl-hystidyl-lysine,20
µg/ml), as previously reported (5). Since SST (5
nM) that was present in the original culture medium
reduced the proliferation rate of these cells, it was removed from the
growth factor mixture (5).
PC mos and PC mos/PTP
[C/S] cells were grown in the same medium
without the growth factors.
PTX (180 ng/ml) treatment was performed in serum-free medium for
18 h before the experimental treatments, as previously reported
(43).
[3H]Thymidine Incorporation Assay
DNA synthesis activity was measured by means of the
[3H]thymidine uptake assay, as previously
reported (17). Briefly, cells were plated at the density
of 5 x 105 in 24-well plates. After 24
h the cells were serum- and growth factor-starved for 48 h.
Subsequently, cells were treated with the test substances for 16
h, and in the last 4 h cells were pulsed with 1 µCi/ml of
[3H]thymidine (Amersham Pharmacia Biotech, Arlington Heights, IL). At the end of the incubation
time, cells were trypsinized (15 min at 37 C), extracted in 10%
trichloroacetic acid (TCA), and filtered under vacuum through fiber
glass filters (GF/A; Whatman, Clifton, NJ). The filters
were then sequentially washed, under vacuum, with 10% and
5% TCA and 95% ethanol. The TCA-insoluble fraction was counted in a
scintillation counter.
MTT Assay
Mitochondrial function, as an index of cell viability, was
evaluated by measuring the levels of mitochondrial dehydrogenase
activity using reduction of MTT as the substrate. Its cleavage to a
purple formazan product by dehydrogenase was quantified
spectrophotometrically measuring the absorbance at 570 nm
(44).
Immunoprecipitation
Total cell lysates (250 µg) were used in immunoprecipitation
experiments. The proteins were incubated with the appropriate
antibodies (1 µg/1 mg of proteins) for 2 h at 4 C, in RIPA
buffer and then with protein A sepharose for an additional hour. After
three washes with RIPA buffer, the immunocomplexes were analyzed in
Western blot. For the PTP immunocomplex assay, the precipitation was
done with IgG-coupled magnetic beads (Dynabeads), since the protein A
caused, per se, hydrolysis of p-nitrophenylphosphate
(pNPP).
PTP Assay
Cells, plated at 50% confluence in 10-cm Petri dishes, were
preincubated with the test substances for 1 h in FCS-free medium
at 37 C in a CO2 incubator. Then the cells were
washed with PBS and mechanically scraped in a buffer containing 0.32
M sucrose, 10 mM Tris, pH 7.5, 5 mM
EGTA, and 1 mM EDTA, and the membranes were isolated as
previously reported (43). Nuclei were removed by
centrifugation at 2,000 x g at 4 C for 10 min.
Membrane fraction was isolated by a further centrifugation at
15,000 x g at 4 C for 60 min, resuspended in a buffer
containing 250 mM HEPES, pH 7.2, 140
mM NaCl, 1% NP40, and PMSF and leupeptin as
protease inhibitors, and assayed for protein content using the method
of Bradford (45) using BSA as a standard and the
Bio-Rad Laboratories, Inc. (Hercules, CA) reagent. Twenty
micrograms of control or treated membranes were used in the PTP assay.
PTP assay was performed using the synthetic substrate pNPP in a
spectrophotometric assay. pNPP is a general phosphatase substrate that
in the presence of inhibitors of Ser/Thr phosphatases is specific for
PTP (13, 17). Membranes were preincubated for 5 min at 30
C in 80 µl volume containing 20 µl of a 5x reaction buffer [250
mM HEPES, pH 7.2, 50 mM
dithiothreitol, 25 mM EDTA, 500
nM microcystin-leucine-arginine (Alamone
Laboratories, Jerusalem, Israel), as a Ser/Thr phosphatase
inhibitor]. The reaction was started by adding 20 µl of 50
mM pNPP, carried out for 30 min at 30 C and
stopped by adding 900 µl of 0.2 N NaOH. The
absorbance of the sample, directly proportional to the amount of
dephosphorylated substrate, was measured at 410 nm (46).
The extinction coefficient for pNPP, at this wavelength is 1.78 x
104
M-1cm-1
(46). In the immunocomplex specific PTP assay, all the
immunoprecipitated proteins (see above) with the specific
-PTP
antibodies were assayed.
mRNA Analysis
The expression of specific mRNAs was evaluated by means of
RT-PCR technique for the SST receptor subtypes and by means of the
Northern blot technique for r-PTP
, as described below.
RNA Isolation and RT-PCR
Total RNA was isolated using the acidic phenol technique
(47). RT-PCR was performed as previously reported
(32). Briefly, 10 µg of total RNA were treated for 45
min with RNAse-free DNAse at 37 C to remove genomic DNA contamination,
phenol/chloroform was extracted and ethanol was precipitated. RT
reaction was performed using oligo-dT(16) primer
and the AMV RT (Amersham Pharmacia Biotech), for 40 min at
42 C. PCR reaction was performed on 10 ng of cDNA as follows: (final
volume 50 µl) 5 min of denaturation at 94 C followed by 40 cycles of
1 min at 94 C, 1 min at 60 C, and 1 min at 72 C, followed by 7 min at
72 C, using the Taq DNA polymerase (2.5 U/reaction)
(Roche Molecular Biochemicals, Indianapolis, IN).
Amplified DNA fragments were then visualized on agarose gel
electrophoresis. The primers used were the following: SSTR1: 5'-sense
primer corresponded to the amino acids 8691 and 3'-antisense primer
corresponded to the amino acids 211217 of SSTR1 sequence; SSTR2:
5'-sense primer corresponded to the amino acids 7177 and 3'-antisense
primer corresponded to the amino acids 195181 of SSTR2 sequence;
SSTR3: 5'-sense primer corresponded to the amino acids 189196 and
3'-antisense primer corresponded to the amino acids 304311 of SSTR3
sequence; SSTR4: 5'-sense primer corresponded to the amino acids
284291 and 3'-antisense primer corresponded to the amino acids
367374 of SSTR4 sequence; SSTR5: 5'-sense primer corresponded to the
amino acids 270276 and 3'-antisense primer corresponded to the amino
acids 354362 of SSTR5 sequence; expected lengths for the amplified
products were the followings: SSTR1 = 395 bp, SSTR2 = 392 bp,
SSTR3 = 370 bp; SSTR4 = 270 bp, SSTR5 = 275 bp.
Northern Blot
Northern blot and hybridization procedures were performed
according to standard procedures (48). A mouse GAPDH probe
was used to ascertain the equal RNA loading.
Immunofluorescence
Indirect immunofluorescence was performed on the different cell
lines, plated on glass coverslips. Cells were fixed in paraformaldehyde
(4% in PBS) for 15 min, washed three times with PBS, and permeabilized
with 0.1% Triton X-100, for 5 min. After washing in PBS, cells were
treated with 0.1 M glycine and incubated in PBS containing
0.2% gelatin. Cells were stained with anti-p27 (Transduction Laboratories, Inc.) antibody in PBS-0.2% gelatin for 1 h,
washed three times in PBS, and incubated with antirabbit fluorescein
isothiocyanate conjugates for 20 min. Finally after washing in PBS,
coverslips were mounted in Moviol (Calbiochem, La Jolla,
CA) and analyzed on a confocal microscope MRC 1024ES (Bio-Rad Laboratories, Inc.).
[Ca++]i Measurement
Cells were plated on 25-mm glass coverslips and transferred to a
35-mm Petri dish. After 24 h cells were serum starved for an
additional 24 h. On the day of the experiment cells were washed
for 10 min with a balanced salt solution (HEPES 10 mM, pH
7.4; NaCl, 150 mM; KCl, 5.5 mM;
CaCl2, 1.5 mM;
MgSO4, 1.2 mM; glucose, 10
mM). Then cells were loaded with Fura-2 penta-acetoxymethyl
ester (4 µM) (Calbiochem) for 20 min at room
temperature. For fluorescence measurements, coverslips were mounted on
a coverslip-chamber, and fura-2 fluorescence was imaged with an
inverted diaphot microscope (Nikon, Melville, NY) using a
Nikon 40X/1.3 NA Fluor DL objected lens. Fluorescence
(ratio 340/380) was then evaluated and converted in
[Ca++]i using the
Quanticell apparatus (Visitech, London, UK), as previously reported
(49). Calibration of fluorescence signals was performed as
described (49). The values of the
[Ca++]i were calculated
using Quanticell software, according to the equation of Grynkiewicz
et al. (50).
Statistical Analysis
Experiments were performed in quadruplicate and repeated at
least three times. Statistical analysis was performed by means of
one-way ANOVA. A P value less than or equal to 0.05 was
considered statistically significant.
 |
ACKNOWLEDGMENTS
|
---|
We would like to thank D. Noonan for scientific discussion.
 |
FOOTNOTES
|
---|
This work was supported by grants from Consiglio Nazionale delle
Ricerche 98.03031.Ct04 and 99.02482.Ct04 (to T.F. and Italian
Association for Cancer Research (AIRC, 1999) and contract
QRTL-199900908 by the European Union (to G.S.)
Abbreviations: [Ca++]i, Intracellular
Ca++ concentration; CDK, cyclin-dependent kinase; IRß,
insulin receptor-ß; MEK, MAPK kinase; MTT, 3-(4,
5-dimethylthiazol-2-yl)-2,5, diphenyl tetrazolium bromide; pNPP,
p-nitrophenylphosphate; PSI, ZIE [Ot-Bu]-A-leucinal;
PTP, phosphotyrosine phosphatase; PTX, pertussis toxin; SST,
somatostatin; SSTR, a family of five different G protein-coupled
receptors; TCA, trichloroacetic acid; w.t., wild-type.
Received for publication April 10, 2001.
Accepted for publication June 19, 2001.
 |
REFERENCES
|
---|
-
Reichlin S 1987 Somatostatin (part 1 and 2). N Engl
J Med 30:14941501, 15561563
-
Florio T, Schettini G 1996 Multiple intracellular effectors
modulate physiological functions of the cloned somatostatin receptors.
J Mol Endocrinol 17:89100[Free Full Text]
-
Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JGM,
Lamberts SWJ 1987 Somatostatin receptors in human endocrine tumors.
Cancer Res 47:551558[Abstract]
-
Dy DY, Whitehead RH, Morris DL 1992 SMS 201995 inhibits
in vitro and in vivo growth of human colon
cancer. Cancer Res 52:917923[Abstract]
-
Florio T, Scorziello A, Fattore M, et al. 1996 Somatostatin
inhibits PC C13 thyroid cell proliferation through the modulation of
phosphotyrosine activity. J Biol Chem 271:61296136[Abstract/Free Full Text]
-
Prévost G, Foehrl E, Thomas F, et al. 1991 Growth of
human breast cancer cell lines is inhibited by the somatostatin analog
BIM23014. Endocrinology 29:323329
-
Qin Y, Schally AV, Willems G 1991 Somatostatin analogues
RC-160 inhibits the growth of transplanted colon cancer in rats. Int J
Cancer 47:765770[Medline]
-
Taylor JE, Moreau J-P, Baptiste L, Moody TW 1990 Octapeptide
analogues of somatostatin inhibit the clonal growth and vasoactive
intestinal peptide-stimulated cyclic AMP formation in human small cell
lung cancer cells. Peptides 12:839843[CrossRef]
-
Reubi JC, Laissue JA 1995 Multiple actions of somatostatin in
neoplastic disease. Trends Pharmacol Sci 16:110115[CrossRef][Medline]
-
Albini A, Florio T, Giunciuglio D, et al. 1999 Somatostatin
controls Kaposi sarcoma growth through inhibition of angiogenesis.
FASEB J 13:647655[Abstract/Free Full Text]
-
Sharma K, Patel Y, Srikant CB 1996 Subtype-selective induction
of wild-type p53 and apoptosis, but not cell cycle arrest, by human
somatostatin receptor 3. Mol Endocrinol 10:16881696[Abstract]
-
Liebow C, Reilly C, Serrano M, Schally AV 1989 Somatostatin
analogues inhibit growth of pancreatic cancer by stimulating tyrosine
phosphatase. Proc Natl Acad Sci USA 86:20032007[Abstract]
-
Pan MG, Florio T, Stork PJS 1992 G protein activation of a
hormone-stimulated protein-tyrosine phosphatase in human tumor cells.
Science 256:12151217[Medline]
-
Buscail L, Delesque N, Estève J-P, et al. 1994 Stimulation of tyrosine phosphatase and inhibition of cell
proliferation by somatostatin analogues: mediation by human
somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91:23152319[Abstract]
-
Florio T, Rim C, Hershberger RE, Loda M, Stork PJS 1994 The
somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase
activity in CHOk1 cells. Mol Endocrinol 8:12891297[Abstract]
-
Hierowski MT, Liebow C, du Sapin K, Schally AV 1985 Stimulation by somatostatin of dephosphorylation of membrane proteins
in pancreatic cancer MIA PaCa2 cell line. FEBS Lett 179:252256[CrossRef][Medline]
-
Florio T, Pan MG, Newman B, Hershberger RE, Civelli O, Stork
PJS 1992 Dopaminergic inhibition of DNA synthesis in pituitary
tumor cells is associated with phosphotyrosine phosphatase activity.
J Biol Chem 267:2416924172[Abstract/Free Full Text]
-
Lee MT, Liebow C, Kamer AR, Schally AV 1991 Effect of
epidermal growth factor and analogues of luteinizing hormone-releasing
hormone and somatostatin on phosphorylation and dephosphorylation of
tyrosine residues of specific protein substrates in various tumors.
Proc Natl Acad Sci USA 88:16561660[Abstract]
-
Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T 1996 Evidence for coupling of phosphotyrosine phosphatase to
gonadotropin-releasing hormone receptor in ovarian carcinoma membrane.
Cancer 77:132137[CrossRef][Medline]
-
Bedecs K, Elbaz N, Sutren M, et al. 1997 Angiotensin II type 2
receptors mediate inhibition of mitogen-activated protein kinase
cascade and functional activation of SHP-1 tyrosine phosphatase.
Biochem J 325:449454[Medline]
-
Neel B 1993 Structure and function of SH2-domain containing
tyrosine phosphatase. Semin Cell Biol 4:419432[CrossRef][Medline]
-
Srikant CB, Shen SH 1996 Octapeptide somatostatin analog SMS
201995 induces translocation of intracellular PTP1C to membranes in
MCF-7 human breast adenocarcinoma cells. Endocrinology 137:34613468[Abstract]
-
Zeggari J, Estéve J-P, Rauly I, et al. 1994 Co-purification of a protein tyrosine phosphatase with activated
somatostatin receptors from rat pancreatic acinar membranes. Biochem J 303:441448[Medline]
-
Lopez F, Esteve J-P, Buscail L, et al. 1997 The tyrosine
phosphatase SHP-1 associates with the sst2 somatostatin receptor and is
an essential component of sst2-mediated inhibitory growth
signaling. J Biol Chem 272:2444824454[Abstract/Free Full Text]
-
Reardon DR, Dent P, Wood SL, Kong T, Sturgill TW 1997 Activation in vitro of somatostatin receptor subtypes 2, 3,
or 4 stimulates protein tyrosine phosphatase activity in membranes from
ras-transformed NIH3T3 cells: co-expression with catalytically
inactive SHP-2 blocks responsiveness. Mol Endocrinol 11:10621069[Abstract/Free Full Text]
-
Florio T, Yao H, Carey KD, Dillon TJ, Stork PJS 1999 Somatostatin activation of MAP kinase via somatostatin receptor 1
(SSTR1) Mol Endocrinol 13:2437[Abstract/Free Full Text]
-
Colas B, Cambillau C, Buscail L, et al. 1992 Stimulation of a
membrane tyrosine phosphatase activity by somatostatin analogues in rat
pancreatic acinar cells. Eur J Biochem 207:10171024[Abstract]
-
Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M,
Vecchio G 1987 One- and two step transformations of rat thyroid
epithelial cells by retroviral oncogenes. Mol Cell Biol 7:33653370[Medline]
-
Berlingieri MT, Akamizu T, Fusco A, et al. 1990 Thyrotropin
receptor gene expression in oncogene-transfected rat thyroid cells:
correlation between transformation, loss of thyrotropin-dependent
growth and loss of thyrotropin receptor gene expression. Biochem
Biophys Res Commun 173:172178[Medline]
-
Berlingieri MT, Portella G, Grieco M, Fusco A 1988 Cooperation
between polyomavirus middle T gene and the human c-myc oncogene on a
rat thyroid epithelial differentiated cell line: a model of in
vitro progression. Mol Cell Biol 8:226230[Medline]
-
Berlingieri MT, Santoro M, Battaglia C, Grieco M, Fusco A 1993 The adenovirus E1A gene blocks the differentiation of a thyroid
epithelial cell line, however the neoplastic phenotype is achieved only
after cooperation with other oncogenes. Oncogene 8:249255[Medline]
-
Florio T, Scorziello A, Thellung S, et al. 1997 Oncogene
transformation of PC C13 clonal thyroid cell line that induces an
autonomous pattern of proliferation that correlates with loss of
basal and stimulated phosphotyrosine phosphatase activity.
Endocrinology 138:37563763[Abstract/Free Full Text]
-
Zhang L, Martelli ML, Battaglia C, et al. 1997 Thyroid cell
transformation inhibits the expression of a novel rat protein tyrosine
phosphatase. Exp Cell Res 235:6270[CrossRef][Medline]
-
Trapasso F, Iuliano R, Stella A, et al. 2000 Rat protein
tyrosine phosphatase
suppresses the neoplastic phenotype of
retrovirally transformed thyroid cells through the stabilization of the
p27 protein. Mol Cell Biol 20:92369246[Abstract/Free Full Text]
-
Patel Y 1999 Somatostatin and its receptor family. Front
Neuroendocrinol 20:157198[CrossRef][Medline]
-
Hoshino R, Tanimura S, Watanabe K, Kataoka T, Kohono M 2001 Blockade of the extracellular signal-regulated kinase pathway induces
marked G1 cell cycle arrest an apoptosis in tumor cells in which this
pathway is constitutively activated. Up-regulation of
p27kip1. J Biol Chem 276:26862692[Abstract/Free Full Text]
-
Walchli S, Curchod M-L, Pescini Gobert R, Arkinstall S, Hooft
van Huijsduijnen R 2000 Identification of tyrosine phosphatases that
dephosphorylate the insulin receptor. J Biol Chem 275:97929796[Abstract/Free Full Text]
-
Bousquet C, Delesque N, Lopez F, et al. 1998 sst2 Somatostatin
receptor mediates negative regulation of insulin receptor signalling
through the tyrosine phosphatase SHP-1. J Biol Chem 273:70997106[Abstract/Free Full Text]
-
Pulido R, Zuniga A, Ullrich A 1998 PTP-SL and STEP protein
tyrosine phosphatases regulate the activation of the extracellular
signal-regulated kinases ERK1 and ERK2 by association through a kinase
interaction motif. EMBO J 17:73377350[Abstract/Free Full Text]
-
Medina DL, Velasco J, Santisteban P 1999 Somatostatin is
expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated
down regulation of the cyclin dependent kinase inhibitor
p27kip1. Endocrinology 140:8795[Abstract/Free Full Text]
-
Medina DL, Toro MJ, Santisteban P 2000 Somatostatin interferes
with thyrotropin-induced G1-S transition mediated by cAMP-dependent
protein kinase and phosphatidyl inositol 3-kinase. J Biol Chem 275:1554915556[Abstract/Free Full Text]
-
Pages P, Benali N, Sain-Laurent N, et al. 1999 sst2
Somatostatin receptor mediates cell cycle arrest and induction of
p27kip1. Proc Natl Acad Sci USA 274:1518615193
-
Schettini G, Florio T, Meucci O, et al. 1989 Somatostatin
inhibition of adenylate cyclase activity in different brain areas.
Brain Res 492:6571[CrossRef][Medline]
-
Florio T, Thellung S, Amico C, et al. 1998 The prion protein
fragment 106126 induces apoptotic cell death and impairment of L-type
voltage sensitive calcium channel activity in the GH3 cell line. J
Neurosci Res 54:341352[CrossRef][Medline]
-
Bradford MM 1976 A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the principle
of protein dye binding. Anal Biochem 72:248254[CrossRef][Medline]
-
Dunphy WG, Kumagai A 1991 The cdc25 protein contains an
intrinsic phosphatase activity. Cell 67:189196[Medline]
-
Chomczinsky P, Sacchi N 1987 Single step method of RNA
isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem 162:156159[CrossRef][Medline]
-
Sambrook J, Fritch EF, Maniatis T 1989 Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor,
NY: Cold Spring Harbor Laboratory
-
Florio T, Thellung S, Arena S, et al. G 1999 Somatostatin and
its analogue lanreotide inhibit the proliferation of dispersed human
non-functioning pituitary adenoma cells, in vitro. Eur J
Endocrinol 141:396408[Medline]
-
Grynkiewicz G, Poenie M, Tsien RY 1985 A new generation of
calcium indicators with greatly improved fluorescence properties.
J Biol Chem 260:34403450[Abstract]